Saxagliptin is non-inferior to glipizide in patients with type 2 diabetes mellitus inadequately controlled on metformin alone: a 52-week randomised controlled trial-Reference-Cited by-同舟云学术

Saxagliptin is non-inferior to glipizide in patients with type 2 diabetes mellitus inadequately controlled on metformin alone: a 52-week randomised controlled trial

Published:2010-09-16 Issue:12 Volume:64 Page:1619-1631
ISSN:1368-5031
Container-title:International Journal of Clinical Practice
language:en
Short-container-title:

Author:

Göke B.,Gallwitz B.,Eriksson J.,Hellqvist Å.,Gause-Nilsson I.,

Publisher

Hindawi Limited

Subject

General Medicine

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/j.1742-1241.2010.02510.x/fullpdf

Reference41 articles.

1. Medical antihyperglycaemic treatment of type 2 diabetes mellitus: update of the evidence-based guideline of the German Diabetes Association;Matthaei;Exp Clin Endocrinol Diabetes,2009

2. Future perspectives for insulinotropic agents in the treatment of type 2 diabetes-DPP-4 inhibitors and sulphonylureas;Gallwitz;Diabetes Obes Metab,2010

3. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes;Nathan;Diabetes Care,2009

4. DPP-4 inhibitors and their potential role in the management of type 2 diabetes;Barnett;Int J Clin Pract,2006

5. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study;Stratton;BMJ,2000

Cited by 146 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Profiles of sulfonylurea use in Diabetes Mellitus type 2: an analysis of clinical practice over the last 10 years;Diabetes Research and Clinical Practice;2024-08

2. Efficacy and Safety of DPP-4 Inhibitors and Metformin Combinations in Type 2 Diabetes: A Systematic Literature Review and Network Meta-Analysis;Diabetes, Metabolic Syndrome and Obesity;2024-06

3. Newer Pharmacologic Treatments in Adults With Type 2 Diabetes: A Systematic Review and Network Meta-analysis for the American College of Physicians;Annals of Internal Medicine;2024-05

4. Cost-Utility Analysis of Dapagliflozin Compared to Sulfonylureas for Type 2 Diabetes as Second-Line Treatment in Indian Healthcare Payer’s Perspective;ClinicoEconomics and Outcomes Research;2021-10

5. Cost-Effectiveness of Dipeptidylpeptidase-4 Inhibitors Added to Metformin in Patients With Type 2 Diabetes in China;Frontiers in Endocrinology;2021-08-13